Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid art ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

This summary covers several health-related news, including Germany's bird flu outbreak, Bristol Myers' lawsuit victory, ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

The U.S. National Transportation Safety Board on Monday said more than 40 foreign operators of Boeing 737 airplanes may be ...

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

New Jersey experiences job losses, layoffs in key industries, and healthcare challenges. Get the full report on the state's ...